Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (221-230 of 910) with videos related to

Pageof 91
Sort By:
Pharmacotherapy|October 27, 2010
Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registryJohn W Devlin, Joseph F Dasta, Kurt Kleinschmidt, et al.
JAMA|May 7, 2009
Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary interventionRajendra H Mehta, Aijing Z Starr, Renato D Lopes, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
Critical Pathways in Cardiology|September 7, 2007
Summary of evidence regarding hospital strategies to reduce door-to-balloon times for patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionElizabeth H Bradley, Brahmajee K Nallamothu, Jeptha P Curtis, et al.
European Heart Journal|October 31, 2007
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMIMichael C Tjandrawidjaja, Yuling Fu, Hussein Al-Khalidi, et al.
Resuscitation|May 2, 2016
Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: Results from a statewide quality improvement initiativeDavid A Pearson, R Darrell Nelson, Lisa Monk, et al.
Thrombosis and Haemostasis|March 7, 2021
Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies AheadEnrico Fabris, Serge Korjian, Barry S Coller, et al.
Circulation. Arrhythmia and Electrophysiology|March 4, 2021
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE TrialSana M Al-Khatib, Hillary Mulder, Daniel Wojdyla, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
American Heart Journal|June 15, 2018
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trialRenato D Lopes, Amit N Vora, Danny Liaw, et al.
Pageof 91

Showing results (221-230 of 910) with videos related to

Sort By:
Pageof 91
Pharmacotherapy|October 27, 2010
Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registryJohn W Devlin, Joseph F Dasta, Kurt Kleinschmidt, et al.
JAMA|May 7, 2009
Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary interventionRajendra H Mehta, Aijing Z Starr, Renato D Lopes, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialChristopher B Granger, John J V McMurray, Salim Yusuf, et al.
Critical Pathways in Cardiology|September 7, 2007
Summary of evidence regarding hospital strategies to reduce door-to-balloon times for patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionElizabeth H Bradley, Brahmajee K Nallamothu, Jeptha P Curtis, et al.
European Heart Journal|October 31, 2007
Failure of investigator adherence to electrocardiographic entry criteria is frequent and influences clinical outcomes: lessons from APEX-AMIMichael C Tjandrawidjaja, Yuling Fu, Hussein Al-Khalidi, et al.
Resuscitation|May 2, 2016
Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: Results from a statewide quality improvement initiativeDavid A Pearson, R Darrell Nelson, Lisa Monk, et al.
Thrombosis and Haemostasis|March 7, 2021
Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies AheadEnrico Fabris, Serge Korjian, Barry S Coller, et al.
Circulation. Arrhythmia and Electrophysiology|March 4, 2021
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE TrialSana M Al-Khatib, Hillary Mulder, Daniel Wojdyla, et al.
Lancet (London, England)|September 19, 2003
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialSalim Yusuf, Marc A Pfeffer, Karl Swedberg, et al.
American Heart Journal|June 15, 2018
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trialRenato D Lopes, Amit N Vora, Danny Liaw, et al.
Pageof 91